Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
      QxMD      Google Scholar   
Citation:
Leukemia vol 35 (10) 2854-2861
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
Yes
Book Volume:
11
Parents:
3251  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Pharmacyclics  
Grants:
U10CA180821, U10CA180882, U24CA196171; UG1CA232760, UG1CA233180, UG1CA233253, UG1CA233327, UG1CA233331, R35CA198183, R01CA192928, U10CA180863 (CCTG)  
Corr. Author:
 
Authors:
                                         
Networks:
IL017, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-OH007, OH070, SCOR   
Study
Alliance-A041202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Article